PCVX · Vaxcyte, Inc.

Vaxcyte’s Q1 2026 financial results reflect a deliberate and substantial ramp-up in clinical and manufacturing execution across its PCV franchise, particularly for VAX-31. The $320.6 million net loss — more than double the prior-year quarter — was driven almost entirely by a $164.7 million increase in R&D expenses, which management explicitly attributed to expanded manufacturing activities supporting potential commercial launch, clinical trial costs tied to the initiation and full enrollment of the three OPUS Phase 3 trials (totaling 6,191 adults dosed), and higher personnel costs from R&D headcount growth. G&A expenses remained flat year-over-year, confirming that spending acceleration is operationally targeted, not broad-based. Critically, the company significantly de-risked its near-term capital position: cash rose to $2.74 billion as of March 31, 2026, fueled by $632.5 million in gross proceeds from its February 2026 public equity offering — a strategic move that extends the cash runway to fund pivotal data readouts (OPUS-1 in Q4 2026, OPUS-2/3 and infant Phase 2 in H1 2027) and the planned mid-2026 initiation of the VAX-A1 Phase 1 study. Management’s commentary underscores confidence in the OPUS program’s design and timeline, framing OPUS-1 as a head-to-head noninferiority trial against both Prevnar 20® and Capvaxive®, with potential superiority on 11 incremental serotypes — positioning VAX-31 not just as another PCV, but as a new benchmark. With no revenue generation and no forward guidance disclosed, the financials serve purely as a capital deployment signal: this is a high-intensity, late-stage clinical investment phase where cash utilization directly maps to value inflection points over the next 12–18 months.